Bionomics EBITDA 2022-2024 | NEUP
Bionomics ebitda from 2022 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Bionomics Annual EBITDA
(Millions of US $) |
| 2024 |
$-17 |
| 2023 |
$-21 |
| 2022 |
$-15 |
| 2021 |
$-4 |
Bionomics Quarterly EBITDA
(Millions of US $) |
| 2024-09-30 |
$-3 |
| 2024-06-30 |
|
| 2023-09-30 |
$-5 |
| 2023-06-30 |
|
| 2022-12-31 |
|
| 2022-06-30 |
|
| 2021-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.010B |
$0.000B |
|
Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.
|
